Poor
Not Aligned
Patient Risk:
High
Summary
Only a minority of extracted claims are verifiable against the provided FDA label excerpts (e.g., FXa mechanism, dose adjustment/transition INR <2.0, and availability of andexanet alfa for adult reversal). Most efficacy comparative statistics, safety assertions, monitoring/interaction generalizations, and many warfarin-specific or dosing/renal-threshold claims are not supported by the provided label sections. Several claims are therefore unsupported relative to the provided label content.
Category Scores
Accurate Statements
Eliquis (apixaban) targets factor Xa to inhibit clotting.
Supported by 11 DESCRIPTION; 12.1 Mechanism of Action (apixaban is described as a selective inhibitor of FXa).
Eliquis reversal agent is Andexxa (andexanet alfa) approved.
Supported by 2.7 Administration Options (Reversal of Anticoagulant Effect): a specific reversal agent (andexanet alfa) is available for adults.
Switching from warfarin to Eliquis requires INR <2.0.
Supported by 2.5 Converting from or to ELIQUIS: start ELIQUIS when INR is below 2.0.
Eliquis dosing may be 2.5 mg for some patients.
Supported by label discussion of 2.5 mg twice daily (e.g., interaction management section) and availability of 2.5 mg tablets (11 DESCRIPTION).
Unsupported Statements
Eliquis (apixaban) is a blood thinner used to prevent strokes in patients with atrial fibrillation (AFib).
Provided label input does not include AFib stroke-prevention wording in Indications content.
Eliquis (apixaban) is used to treat or prevent blood clots in conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE).
Provided label input does not include DVT/PE indication wording.
Eliquis is a direct oral anticoagulant (DOAC).
Not supported by the provided label excerpts.
Warfarin is a blood thinner used to prevent strokes in patients with atrial fibrillation (AFib).
No warfarin labeling content is provided in the input for verification.
Warfarin is used to treat or prevent blood clots in conditions like deep vein thrombosis (DVT) or pulmonary embolism (PE).
No warfarin labeling content is provided in the input for verification.
Warfarin is a vitamin K antagonist.
No warfarin labeling content is provided in the input for verification.
Warfarin broadly disrupts clotting factors II, VII, IX, and X.
No warfarin labeling content is provided in the input for verification.
Eliquis requires no routine blood monitoring.
Not supported by provided label excerpts (12.2 indicates clotting tests are not useful for monitoring the anticoagulation effect, but this does not equate to 'no monitoring' generally).
Warfarin demands frequent INR tests to adjust dosing.
No warfarin labeling content is provided in the input for verification.
In the ARISTOTLE trial, Eliquis reduced stroke/systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% annual rate).
Clinical study efficacy statistics are not present in provided label excerpts.
In the ARISTOTLE trial, Eliquis reduced major bleeding by 31% compared to warfarin.
Clinical study bleeding statistics are not present in provided label excerpts.
In the AMPLIFY trial, Eliquis matched warfarin in preventing recurrent clots (2.3% vs. 2.6%).
Clinical study efficacy statistics are not present in provided label excerpts.
In the AMPLIFY trial, Eliquis reduced major bleeding by 69% compared to warfarin.
Clinical study bleeding statistics are not present in provided label excerpts.
Meta-analyses confirm DOACs like Eliquis lower stroke risk by 19% versus warfarin in AFib.
Meta-analysis comparative statistics are not present in provided label excerpts.
Meta-analyses confirm DOACs like Eliquis lower intracranial hemorrhage by 50% versus warfarin in AFib.
Meta-analysis comparative statistics are not present in provided label excerpts.
Eliquis has a lower overall bleeding risk.
No such comparative 'overall bleeding risk' statement is supported in provided label excerpts.
In the ARISTOTLE trial, clinically relevant non-major bleeding dropped 29% with Eliquis.
Clinical study statistic is not present in provided label excerpts.
Gastrointestinal bleeding is higher with Eliquis than warfarin in some analyses.
No such comparative GI bleeding statement is present in provided label excerpts.
Eliquis avoids warfarin's skin necrosis or purple toe syndrome.
No warfarin-specific adverse reaction comparison is present in provided label excerpts.
Warfarin risks increase with diet, alcohol, or drug interactions affecting vitamin K.
No warfarin-specific interaction/diet statements are present in provided label excerpts.
Warfarin dosing is variable, daily, and INR-adjusted.
No warfarin dosing description is present in provided label excerpts.
Eliquis requires no monitoring.
Not supported as written; provided label excerpts do not state 'requires no monitoring' broadly.
Warfarin requires frequent INR blood tests.
No warfarin labeling content is provided in the input for verification.
Eliquis has minimal food/drug interactions.
Not supported by provided label excerpts.
Warfarin reversal options include vitamin K, PCC, or FFP.
No warfarin reversal content is provided in the input label excerpts.
Eliquis offers predictable dosing without lifestyle restrictions, improving adherence.
No adherence/lifestyle restriction statements are present in provided label excerpts.
Eliquis costs $500-600 monthly without insurance.
Pricing is not part of FDA label excerpts provided.
Warfarin costs $10-50 (generic).
Pricing is not part of FDA label excerpts provided.
Long-term, Eliquis may save via fewer tests/hospitalizations.
Health economics statements are not present in provided label excerpts.
Medicare covers both Eliquis and warfarin, but copays vary.
Coverage/copay statements are not present in provided label excerpts.
Warfarin is preferred in resource-limited settings.
No such preference/resource statements are present in provided label excerpts.
AHA/ACC guidelines favor DOACs like Eliquis as first-line for non-valvular AFib due to better safety/efficacy.
Guideline endorsement statements are not present in provided label excerpts.
Warfarin suits mechanical heart valves.
No such warfarin-specific suitability statement is present in provided label excerpts.
Warfarin suits antiphospholipid syndrome.
No such warfarin-specific suitability statement is present in provided label excerpts.
Warfarin suits severe kidney disease.
No such warfarin-specific suitability statement is present in provided label excerpts.
Eliquis is cleared 27% renally.
No renal clearance percentage is present in provided label excerpts.
Eliquis should be avoided if CrCl <15 mL/min.
No CrCl threshold appears in provided label excerpts.
Warfarin reversal options include vitamin K, PCC, or FFP.
Not supported; reversal content provided concerns apixaban reversal options only.
Eliquis major bleeding rates are 2-3% per year.
No numeric bleeding rate is present in provided label excerpts.
No difference in mortality between Eliquis and warfarin is stated.
Not present in provided label excerpts.
Contradictions
Important Omissions
Key FDA contraindications content for Eliquis (e.g., active pathological bleeding; severe hypersensitivity) was not addressed by the AI claims list provided.
Importance:
High
Boxed warnings content verification (premature discontinuation risk; spinal/epidural hematoma) was not reflected in the provided extracted claims.
Importance:
High
General bleeding warning and drug interactions affecting hemostasis (e.g., concomitant antiplatelet/anticoagulants/NSAIDs) were largely omitted in the extracted claims.
Importance:
High
Renal impairment dosing/avoidance details were omitted/incorrectly asserted (CrCl threshold not supported by provided excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple extracted claims relevant to safety (comparative bleeding/efficacy statistics, monitoring requirements, drug interaction breadth, and a CrCl avoidance threshold) are not supported by the provided label excerpts. The absence of contraindications/boxed warnings discussion further limits safe alignment with the label content provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most extracted efficacy/safety/statistical and warfarin-comparative claims are not supported by the provided FDA label excerpts; several safety-critical assertions (e.g., CrCl threshold, monitoring/interaction generalizations) are unsupported.
Suggested Improvement
Restrict claims to label-verifiable statements from the provided excerpts (e.g., FXa mechanism; INR<2.0 transition; andexanet alfa availability for adults; dose adjustment rules with combined P-gp/strong CYP3A4 inhibitors) and include/align contraindications and boxed-warning concepts present in the label excerpts when making safety-related statements.